Purification of proteins

ABSTRACT

The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.

This application claims priority of U.S. Provisional Application Ser.No. 60/876,330 filed Dec. 21, 2006, the disclosure of which isincorporated herein by reference.

The present invention relates to the purification of biomolecules. Moreparticularly, it relates to the purification of biomolecules such asproteins, polypeptides, antibodies and the like, by a solubilizedpolymer to remove impurities from a solution/suspension by a controlledprecipitation mechanism.

BACKGROUND OF THE INVENTION

The general process for the manufacture of biomolecules, such asproteins, particularly recombinant proteins typically involves two mainsteps: (1) the expression of the protein in a host cell, followed by (2)the purification of the protein. The first step involves growing thedesired host cell in a bioreactor to effect the expression of theprotein, Some examples of cell lines used for this purpose includeChinese hamster ovary (CHO) cells, myeloma (NSO) cells, bacterial cellssuch as e-coli and insect cells. Once the protein is expressed at thedesired levels, the protein is removed from the host cell and harvested.In some instances the protein has been expressed outside of the cell andin others it is still within the cell that must be lysed to allow oneaccess to the protein of interest. Suspended particulates, such ascells, cell fragments, lipids and other insoluble matter are typicallyremoved from the protein-containing fluid by filtration orcentrifugation, resulting in a clarified fluid containing the protein ofinterest in solution as well as other soluble impurities.

The second step involves the purification of the harvested protein toremove impurities which are inherent to the process. Examples ofimpurities include host cell proteins (HCP, proteins other than thedesired or targeted protein), nucleic acids, endotoxins, viruses,protein variants and protein aggregates.

This purification typically involves several chromatography steps, whichcan include affinity, ion exchange hydrophobic interaction, etc. Oneexample of chromatography process train for the purification of proteinsinvolves protein-A affinity, followed by cation exchange, followed byanion exchange. The protein-A column captures the protein of interest ortarget protein by an affinity mechanism while the bulk of the impuritiespass through the column to be discarded. The protein then is recoveredby elution from the column. Since most of the proteins of interest haveisoelectric points (PI) in the basic range (8-9) and therefore beingpositively charged under normal processing conditions (pH below the PIof the protein), they are bound to the cation exchange resin in thesecond column. Other positively charged impurities are also bound tothis resin. The protein of interest is then recovered by elution fromthis column under conditions (pH, salt concentration) in which theprotein elutes while the impurities remain bound to the resin. The anionexchange column is typically operated in a flow through mode, such thatany negatively charged impurities are bound to the resin while thepositively charged protein of interest is recovered in the flow throughstream. This process results in a highly purified and concentratedprotein solution.

Other alternative methods for purifying proteins have been investigatedin recent years, one such method involves a flocculation technique. Inthis technique, a soluble polyelectrolyte is added to a clarified orunclarified cell culture broth to capture the impurities thereby forminga flocculant, which is allowed to settle and can be subsequently removedfrom the protein solution.

The main drawback of this flocculation technique is that it requiresthat the polyelectrolyte be added in the exact amount needed to removethe impurities. If too little flocculent is added, impurities willremain in the protein solution and if too much flocculent is added, theexcess polyelectrolyte needs to be removed from the resulting solution.The exact level of impurities in the broth is extremely difficult topredict due to the relatively large degree of variability in the process(from batch to batch) as well as the vast differences between processesto produce different proteins. Removing any excess polyelectrolyte ispractically impossible because it is a soluble material and thus it iscarried through the process as an undesirable impurity.

What is needed is a better process for purifying biomolecules.

SUMMARY OF THE INVENTION

The present invention relates to a selectively soluble polymer capableof binding to one or more constituents in a biological materialcontaining stream and the methods of using such a material to purify abiomolecule from such a stream.

In the following description, the term polymer shall mean a polymercapable of binding to one or more constituents in a biological materialcontaining stream unless otherwise stated.

The terms selected biomolecule, target biomolecule or molecule, targetprotein, biomolecule or protein of interest, or similar terms all referto products of a biomolecule manufacturing process.

The polymer is soluble in an aqueous based solvent under a certain setof process conditions such as pH or temperature or salt concentration orthe like and is rendered insoluble and precipitates out of solution upona change in conditions (temperature, pH, salt or the like). While in itssolubilized state, the polymer is capable of binding to a selectedentity within the stream such as impurities (cells, cell fragments,lipids, DNA, RNA, host cell protein, endotoxins, virus, etc) in a cellbroth and remains capable of binding to that entity even after thepolymer is precipitated out of solution. The precipitate can then beeasily removed, such as by being filtered out from the remainder of thestream and the desired biomolecule is recovered and further processed.

The polymer being bound to one or more impurities, it can either bedisposed of or the one or more impurities can be eluted from the polymerand the polymer is then cleaned or sanitized and reused if desired. Itcan also be washed to ensure that any biomolecules of interest have beenrecovered for further use or processing.

It is an object of the present invention to provide a polymer that iscapable of being selectively solubilized in a liquid under certainconditions and to be insoluble and to precipitate out of solution underdifferent conditions in that liquid.

It is another object of the present invention to provide a polymer thatis capable of being selectively solubilized in a liquid under certainconditions and to be insoluble and to precipitate out of solution underdifferent conditions in that liquid and to allow any excess polymer insolution to be recovered from the solution by precipitation.

It is a further object of the present invention to provide a polymerthat is capable of being solubilized under a first certain set ofconditions in the liquid and to be capable of binding to one or moreentities either in the liquid while in its solubilized form and/or toretain the one or more entities or bind to the impurities or have theimpurities bind to it as/after being precipitated from the liquid underdifferent conditions in the liquid.

It is another object of the present invention to provide a polymercapable of being solubilized under certain ranges of pH, temperature,temperature and salt concentration or the like and to have it bind toone or more entities either in the liquid while in its solubilized formand/or to retain the one or more entities or bind to the impurities orhave the impurities bind to it as/after being precipitated under adifferent set of ranges of pH, temperature, temperature and saltconcentration or the like.

It is a further object of the present invention to provide a process forpurifying a selected biomolecule from a biomolecule containing stream byeither having the stream at a given condition or modifying the stream toa given condition and adding a polymer soluble in the stream at thatgiven condition, allowing the solubilized polymer to circulatethroughout the stream, further changing the given condition of thestream so as to cause the polymer to become insoluble in the stream andprecipitate out with one or more entities of the stream, separating thestream from the polymer and processing one or both further.

It is an object to use one or more polymers such as poly(N-vinylcaprolactam), poly(N-acryloylpiperidine), poly(N-vinylisobutyramide),poly (N-substituted acrylamide) including [poly(N-isopropylacrylamide),poly(N,N′-diethylacrylamide), and poly(N-acryloyl-N′-alkylpiperazine)],hydroxyalkylcellulose, copolymers of acrylic acid and methacrylic acidor methacrylic acid and methyl methacrylate, polymers and copolymers of2 or 4-vinylpyridine and chitosan to selectively remove one or moreimpurities from a stream containing impurities along with a desiredbiomolecule.

It is an object to do the process with an overabundance of polymer andrecover substantially all of the polymer as a precipitate from themixture.

It is an additional object of the present invention to provide theprocess based on a polymer which is soluble based upon a conditionselected from temperature, temperature and salt content or pH.

It is another object of the present invention to provide a polymerselected from N-isopropylacrylamide-containing polymers, functionalizedagarose, functionalized polyethylene oxide, cationic and anionicpolyelectrolytes.

It is a further object of the present invention to provide a process forpurifying a selected biomolecule from a biomolecule containing mixtureby setting the mixture to a given condition, modifying a carrier liquidcompatible with the mixture to the same given condition, adding apolymer soluble in the carrier liquid at that given condition to thecarrier liquid, allowing the carrier liquid with the solubilized polymerto the mixture and allowing it to circulate throughout the mixture,changing the given condition of the stream so as to cause the polymer tobecome insoluble in the stream and precipitate out along with one ormore entities of the mixture, separating the mixture from the polymerand processing one or both further.

It is an additional object of the present invention to provide a staticmixer for causing the mixture and solubilized polymer to mix and toallow the polymer to bind to the one or more entities.

It is another object of the present invention to provide that the one ormore entities are impurities in the mixture.

It is a further object of the present invention to provide that the oneor more entities are impurities in the mixture selected from host cellprotein, cells, cell fragments, nucleic acids and endotoxins.

It is an object of the present invention to provide that the one or moreentities are viruses which are either removed or rendered inactive bythe polymer process. For example, viruses may be removed by theprecipitated polymer or they may be rendered inactive by the polymeritself or by the conditions under which the polymer is dissolved intothe mixture or rendered insoluble from the mixture.

It is an additional object of the present invention to provide a processfor the purification of a mixture of biological constituents in a singlestep.

It is another object of the present invention to provide a process forthe purification of a mixture of biological constituents selected fromproteins, polypeptides, monoclonal antibodies, humanized, chimeral oranimal monoclonal antibodies polyclonal antibodies, antibody fragments,multispecific antibodies, immunoadhesins, and C_(H)2/C_(H)3region-containing proteins.

It is a further object of the present invention to provide a process ofhaving a mixture containing a biomolecule of interest at a set range ofconditions that will cause one or more polymers of choice to go intosolution, adding the one or more polymers and having one or morepolymers go into solution, mixing the one or more polymers with entitiesof the mixture, changing the conditions of the mixture to cause the oneor more polymers to precipitate out of solution while retaining one ormore entities of the mixture and then separating the precipitate fromthe remainder of the mixture.

It is a further object of the present invention to provide a carrierliquid for the polymer having conditions suitable to cause the polymerto go into solution in the carrier liquid and then to add the carrierliquid with the dissolved polymer to the mixture.

It is an additional object of the present invention to provide one ormore static mixers to mix the polymer and the mixture.

It is another object of the present invention to provide a process forrecovering a biomolecule of interest directly from a fermentor orbioreactor in which it has been made.

It is a further object of the present invention to provide a process forrecovering a biomolecule of interest from a mixture obtained from afermentor or bioreactor in which it has been made.

It is an additional object of the present invention to provide afiltration step to separate the precipitate from the remainder of themixture.

It is another object of the present invention to provide a normal flowfiltration step to separate the precipitate from the remainder of themixture.

It is a further object of the present invention to provide a tangentialflow filtration step to separate the precipitate from the remainder ofthe mixture.

It is an additional object of the present invention to provide acentrifugation step to separate the precipitate from the remainder ofthe mixture.

It is another object of the present invention to provide a decantationstep to separate the precipitate from the remainder of the mixture.

It is an additional object of the present invention to provide a furtherstep to recover the one or more constituents of the mixture from theprecipitated polymer.

It is a further object of the present invention to provide additionalprocessing to the biomolecule of interest.

It is an additional object of the present invention to provide a furtherstep of formulating the biomolecule in a pharmaceutically acceptablecarrier and using it for various diagnostic, therapeutic or other usesknown for such biomolecules.

It is an object of the present invention to provide a purifiedbiomolecule in one step, directly out of the bioreactor with no furtherprocessing required.

It is an additional object of the present invention to improve theefficiency of the clarification (centrifuge or prefiltration) step sothat the clarifier (centrifuge or prefilter) exhibits enhancedthroughput or capacity.

It is another object of the present invention to improve the efficiencyof the clarification (centrifuge or prefiltration) step so that theresulting clarified mixture is “cleaner” (going into the sterilemembrane filtration step) than a conventional process in which theprecipitation technique has not been effected.

It is an additional object of the present invention to improve theefficiency of the sterile membrane filtration step so that the membranefilter exhibits enhanced throughput (capacity).

It is an additional object of the present invention to provide apurified mixture which enables the improved cleanabiliity of membranefilters and/or chromatography resins that may be used in additionalprocessing following the precipitation step.

It is a further object of the present invention to compress theadditional processing steps into one continuous process.

It is an additional object of the present invention to effect thepurification and recovery of a target molecule with additionalprocessing but without the need for bind and elute chromatography steps.

It is a further object of the present invention to effect thepurification and recovery of a target molecule with additionalprocessing but without the need for any chromatography steps.

It is a further object of the present invention to effect thepurification and recovery of a target molecule with additionalprocessing in a flow through mode.

It is a further object of the present invention to effect thepurification and recovery of a target molecule with additionalprocessing using membrane adsorbers.

It is a further object of the present invention to effect thepurification and recovery of a target molecule with additionalprocessing using a disposable process.

It is a further object of the present invention to effect virusinactivation as part of the precipitation process.

It is a further object of the present invention to use a UF step toconcentrate the target protein after it has been purified and recoveredwith the precipitation technique.

It is an additional object of the present invention to effect thepurification and recovery of a target molecule with additionalprocessing using an enhanced UF (charged UF) process.

IN THE DRAWINGS

FIG. 1 shows a block diagram of a first process according to the presentinvention.

FIG. 2 shows a block diagram of a second process according to thepresent invention.

FIG. 3 shows a block diagram of a third process according to the presentinvention.

FIG. 4 shows a block diagram of a fourth process according to thepresent invention.

FIG. 5 shows a block diagram of a fifth process according to the presentinvention.

FIGS. 6A and B show gel electrophoresis data of Example 11 according tothe present invention.

FIG. 7 shows SDS-PAGE data of Example 11 according to the presentinvention.

DETAILED DESCRIPTION OF THE INVENTION

The invention is to use a liquid phase or solubilized polymer that has acapability, such as affinity or charge or hydrophobicity and the like,to remove undesirable soluble and suspended impurities from a fluidcontaining a desirable biomolecule of interest. Preferred polymers havean affinity or electrostatic ability. The biomolecule of interest isthen recovered and further processed as desired or required.

More specifically, the idea relates to the process of using one or morepolymers soluble in a liquid phase to remove impurities from asolution/suspension by a precipitation mechanism and which polymer canalso be removed, if present, in any excess, by the same mechanism. Byway of example, this idea can best be described in the context ofprotein purification although it can be used to purify any solute fromcomplex mixtures as long as the mechanism of removal applies to thespecific solute of interest.

The one or more polymers can be used in excess unlike flocculants andcan be recovered essentially completely from the mixture by theprecipitation action. This allows one to operate the purification stepwith greater windows of use and without having to calculate the preciseamount of material that needs to be used.

The present concept is based on the fact that certain polymers undergochanges in properties as a result of changes in the environment in whichthey are in. The most common polymer property to change as a result of astimulus is solubility and the most common stimuli are temperature saltconcentration and pH. As an example, a polymer may remain in solution aslong as the pH, salt or temperature is maintained within a certain rangebut it will precipitate out of solution as soon as the pH, salt ortemperature is raised or lowered outside of said range.

Certain polymers, such as poly (N-isopropylacrylamide), agarose,polyethylene oxide, etc. are examples of polymers that exhibitsolubility changes as a result of changes in temperature. Otherpolymers, such as certain catonic and anionic polyelectrolytes,especially poly(4-vinylpyridine), poly(2-vinylpyridine), copolymers of4-vinyl pyridine or 2-vinyl pyridine with other monomers such asstyrene, butyl methacrylate, etc., chitosan and copolymers of acrylicacid or methacrylic acid with other monomers such as methyl methacrylateare examples of polymers that exhibit changes in solubility as a resultof changes in pH and/or salt concentration.

The precise mechanism is not currently known. It may be that thepolymer(s) interact with the entity or entities while in a soluble stateand continue to bind to them upon precipitation. It may also be that thepolymer and/or entity(s) bind to one another as the polymer is in theprocess of precipitating. It may be another mechanism as yet unknown tothe inventor at this time. The inventor does not wish to be bound to anyparticular theory of what mechanism is being used but that the inventionencompasses any all such mechanisms and phenomena.

Depending upon the polymer used, the process used can vary. However, theprocesses will generally involve having one or more conditions of theliquid or the mixture, such as a cell broth, at the correct pH,temperature, temperature and salt concentration or other condition usedto cause the polymer(s) to become soluble and then adding the polymer(s)either directly or already solubilized in a carrier liquid, such aswater, to the mixture. In many instances the mixture will be at theproper condition to allow the polymer(s) to be simply added to themixture. In other instances, the mixture may need to be conditioned ormodified to be at the desired condition. This modification orconditioning can be by modifying the mixture first and then adding thepolymer(s), by adding the polymer(s) to a carrier liquid that isconditioned to the desired state and simply adding it to the mixturesuch that the carrier liquid is sufficient to cause the mixture to thusreach that condition or to do both. The mixture and the solubilized orsoluble polymer(s) are then mixed to ensure the polymer(s) issolubilized, and that the entities of the mixture and the solubilizedpolymer(s) have sufficient and intimate contact with each other. Theconditions of the liquid in the mixture are then changed (pH,temperature, salt content, combinations thereof, etc) that causes thepolymer(s) to become insoluble and precipitate out of the mixture as asolid while either still remaining bound to the one or more entities itcontacted while soluble in the mixture or to bind to the entities as itprecipitates and continue to bind to it thereafter. The precipitate andremaining mixture are then separated such as by centrifugation orfiltration or gravity and time with the liquid portion being decanted.Depending on what was bound to the precipitate, it is either disposed of(if it bound to impurities) or treated (such as by elution and orwashing) one or more times to remove any residual impurities orcontaminants and then sanitized for reuse.

One polymer or a blend of polymers may be used in the present inventionand it is meant to cover both embodiments whenever the term polymer,polymer(s) or one or more polymers is used hereafter.

As discussed above the polymer may be added directly to the conditionedmixture. Alternatively, it can be added to a carrier liquid in which itis soluble and which carrier preferably is also compatible with themixture. One such carrier liquid is water, water adjusted to the correctpH by the addition of acids or bases, another is an aqueous basedsolution such as saline, buffered solutions or blends of water with anorganic solvent such as alcohol. The selection of carrier liquid isdependent on the mixture to which it is added as to what is preferredand tolerated. The polymer is added to the carrier liquid that eitherhas already been conditioned (such as pH adjusted or heated to a desiredtemperature or heated to a desired temperature with the addition of oneor more salts or cooled to the desired temperature with or without oneor more salts) or it can be added and then the carrier is conditioned tocause the solubilizing of the polymer in the carrier. The carrier/soluble polymer blend is then added to the. mixture.

The mixture may be contained in a mixing vessel such as a tapered bottommetal (preferably stainless steel more preferably 304 or 316 L stainlesssteel) or glass vat or tank. Alternatively, especially when a cellculture or microbial or yeast culture is used, it may be the bioreactoror fermentor in which it has been grown. It may also be a disposablebioreactor or fermentor or a disposable mixing bag such as a plastic bagas is available from Millipore Corporation of Billerica, Mass. Themixture and polymer are brought into intimate contact through a mixingaction that may be done by a magnetic stirred bar, a magnetic drivenmixer such as a NovAseptic® mixer available from Millipore Corporationof Billerica Mass., a Lightning-type mixer., a recirculation pump, or arocking motion closed mixing bag or bioreactor or fermentor, such as isshown in US 2005/0063259A1 or an airlift type of mixer or reactor inwhich rising bubbles in the liquid cause a circulatory pattern to beformed.

Alternatively, the mixture and polymer (either by itself or in acarrier) can be in separate containers and mixed in line in a staticblender. The blend can either then go to a container or to a centrifugeor a filter where the polymer is caused to precipitate and theprecipitated polymer and its bound one or more entities is separatedfrom the remainder of the mixture. Then at least the remainder of themixture is further processed.

In another embodiment, the mixture and polymer (either by itself or in acarrier) are blended together in the container holding the mixture andfurther mixed in line in a static blender. The blend is then treated tocause precipitation of the polymer and its bound entity(s). It caneither then go to a container or to a centrifuge or to a filter wherethe precipitated polymer and its bound one or more entities is separatedfrom the remainder of the mixture. Then at least the filtrate is furtherprocessed.

Using centrifugation, one can easily and quickly separate theprecipitated polymer from the remainder of the liquid mixture. Aftercentrifugation, the supernatant, generally the remainder of the mixtureis drawn off. Either the drawn off mixture or the precipitated polymeror both if desired is further processed.

Simple settling of the precipitated solids and decantation of thesupernatant fluid may also be used if desired.

Filtration can be accomplished in a variety of manners. Depending uponthe size of the polymer as it is precipitated; one may use one or morefilters of varying sizes or asymmetries.

The selection of type and size of filter will depend on the volume ofprecipitate to be captured and whether one wishes to further process theprecipitated polymer or just the remainder of the mixture,

Membrane based filters, preferably microporous membranes can be used inthe present invention. Such filters are generally polymeric in natureand can be made from polymers such as but not limited to olefins such aspolyethylene including ultrahigh molecular weight polyethylene,polypropylene, EVA copolymers and alpha olefins, metallocene olefinicpolymers, PFA, MFA, FIFE, polycarbonates, vinyl copolymers such as PVC,polyamides such as nylon, polyesters, cellulose, cellulose acetate,regenerated cellulose, cellulose composites, polysulfone,polyethersulfone, polyarylsulfone, polyphenylsulfone, polyacrylonitrile,polyvinylidene fluoride (PVDF), and blends thereof. The membraneselected depends upon the application, desired filtrationcharacteristics, particle type and size to be filtered and the flowdesired. Preferred membrane based filters include DURAPORE® PVDFmembranes available from Millipore Corporation of Billerica Mass.,MILLIPORE EXPRESS® and MILLIPORE EXPRESS® PLUS or SH_PES membranesavailable from Millipore Corporation of Billerica Mass.

Depending on the mixture, polymer and the nature of component(s) beingremoved the membrane may be hydrophilic or hydrophobic. Preferredmembranes are hydrophilic and are low in protein binding.

The membrane may be symmetric in pore size through out its depth such asDURAPORE® PVDF membranes available from Millipore Corporation ofBillerica Mass., or it may be asymmetric in pore size through itsthickness as with MILLIPORE EXPRESS® and MILLIPORE EXPRESS® PLUS orSH_PES membranes available from Millipore Corporation of Billerica Mass.It may contain a prefilter layer if desired, either as a separateupstream layer or as an integral upstream portion of the membraneitself.

The pore size of the membrane can vary depending upon the polymer andmixture selected. Generally, it has an average pore size of from about0.05 micron to 5 microns, preferably from about 0.05 micron to about 1micron, more preferably from about 0.05 to about 0.65 micron.

The membrane filter may run in a deadend or normal flow (NF) format or atangential flow (TFF) format. The choice is dependent on a number offactors, primarily the user's preference or installed filtrationequipment as either works with the present invention.

Depth filters such as the MILLISTAK+® depth filters, in eitherlenticular or POD format, or POLYGARD® wound filters available fromMillipore Corporation of Billerica Mass. allows one to trap a largevolume of precipitated polymer due to its asymmetric structure and largeholding capacity. This can be useful when the polymer is designed toremove impurities and to leave the target or desired biomolecule in theliquid of the remaining mixture.

FIG. 1 shows a block diagram of a first process of the presentinvention. In the first step 2, the mixture is either conditioned to thecorrect parameter(s) to maintain the polymer of choice in solution or ifthe conditions of the mixture are already such that the polymer(s)become soluble in the mixture, no further conditioning may be required.Also, the polymer(s) may be added as a solid to an unconditioned mixtureand then the mixture (containing the solid polymer(s)) may beconditioned to the correct parameters to dissolve the polymer(s) in themixture. In the second step 4, the polymer(s) is then added to themixture and mixed to cause it to go into solution and to make intimatecontact with all the constituents of the mixture. This may occur in thebioreactor especially if the reactor is a disposable item or in aseparate holding tank if desired. In the third step 6, the mixtureconditions are changed to cause the polymer(s) to precipitate out ofsolution while retaining one or more entities of the mixture with it.The mixture and the precipitated polymer(s) are then separated from eachother in the fourth step 8. As discussed above the precipitate andremaining mixture may be separated by centrifugation or filtration.

FIG. 2 shows a block diagram of a second process of the presentinvention. In the first step 10, the mixture is either conditioned tothe correct parameter(s) to maintain the polymer of choice in solutionbefore, during or after the introduction of the polymer or it is alreadyat the desired condition. In the second step 12 which may occurseparately before, simultaneously or after the first step 10, thepolymer is added to a carrier liquid under conditions that allow it togo into solution. In the third step 14, the polymer in its carrier isthen added to the mixture and mixed to make intimate contact with allthe constituents of the mixture. In the fourth step 16, the mixtureconditions are changed to cause the polymer to precipitate out ofsolution carrying one or more entities of the mixture with it. Themixture and the precipitated polymer are then separated from each otherin the fifth step 18. As discussed above the precipitate and remainingmixture may be separated by centrifugation or filtration in a sixth step20 and the target or desired biomolecule is recovered.

FIG. 3 shows a block diagram of a third process of the presentinvention. In the first step 30, the mixture is either conditioned tothe correct parameter(s) to maintain the polymer of choice in solutionbefore, during or after introduction of the polymer or it is already atthe desired condition. In the second step 32 which may occur separatelybefore, simultaneously or after the first step 30, the polymer is addedto a carrier liquid under conditions that allow it to go into solution.In the third step 34, the polymer in its carrier is then added to themixture through one or more static mixers to make intimate contact withall the constituents of the mixture. In the fourth step 36, the mixtureconditions are changed to cause the polymer to precipitate out ofsolution. The mixture and the precipitated polymer are then separatedfrom each other in the fifth step 38. As discussed above the precipitateand remaining mixture may be separated by centrifugation or filtrationin a sixth step 40 and the target or desired biomolecule is recovered.

FIG. 4 shows a block diagram of the first process of the presentinvention as shown in FIG. 1 with an additional step. In the first step2, the mixture is conditioned to the correct parameter(s), or if theconditions of the mixture are already such that the polymer becomessoluble in the mixture, no further conditioning may be required tomaintain the polymer of choice in solution. Also, the polymer may beadded as a solid to an unconditioned mixture and then the mixture(containing the solid polymer) may be conditioned to the correctparameters to dissolve the polymer in the mixture and maintain thepolymer of choice in solution. In the second step 4, the polymer is thenadded to the mixture and mixed to cause it to go into solution and tomake intimate contact with all the constituents of the mixture. In thethird step 6, the mixture conditions are changed to cause the polymer toprecipitate out of solution. The mixture and the precipitated polymerare then separated from each other in the fourth step 8. In the fifthstep 9, the precipitate is separated from the remaining mixture byfiltration. The filtration maybe by either normal flow or tangentialflow filtration with any of the membranes or depth filters describedabove.

FIG. 5 shows a block diagram of the first process of the presentinvention as shown in FIG. 1 with an additional step. In the first step2, the mixture is conditioned to the correct parameter(s) or if theconditions of the mixture are already such that the polymer becomessoluble in the mixture, no further conditioning may be required tomaintain the polymer of choice in solution. Also, the polymer may beadded as a solid to an unconditioned mixture and then the mixture(containing the solid polymer) may be conditioned to the correctparameters to dissolve the polymer in the mixture to maintain thepolymer of choice in solution. In the second step 4, the polymer is thenadded to the mixture and mixed to cause it to go into solution and tomake intimate contact with all the constituents of the mixture. In thethird step 6, the mixture conditions are changed to cause the polymer toprecipitate out of solution. The mixture and the precipitated polymerare then separated from each other in the fourth step 8. In the fifthstep 7, the precipitate is separated from the remaining mixture bycentrifugation.

The change in stimuli may be gradual or it may be done substantiallyinstantaneous. For example, a change in pH can be done by slowly addinga pH changing material to the liquid to change the pH slowly over a spanof several minutes or even hours. Alternatively, for example, a suitableamount of pH changing material can be added to the liquid at one time tocause the change in pH to occur more rapidly. More control has beenfound in general with incremental changes rather than immediate changesfor most processes.

Examples of cationic polyelectrolytes that exhibit this selectivesolubility behavior include chitosan, polyvinylpyridines (PVPs) andcopolymers of PVPs such as poly(2 vinylpyridine) (P2VP) or poly(4vinylpyridine) (P4VP), polyvinylpyridine-co-styrene (PVP-S),polyvinylpyridine-co-butyl methacrylate (PVP-BMA) as well as otherprimary, secondary and tertiary amine-containing polymers. Thesepolymers are soluble at a pH lower than about 6-7 and are insoluble at apH greater than about 5-7. When in solution, these polymers willprecipitate if the pH is raised above this critical range (ph=5˜7). Inthe context of protein purification, a solution of said cationicpolyelectrolyte can be added to a fluid containing a biomolecule ofinterest, such as a protein in the presence of other impurities. Thisfluid can be for example a cell culture fluid. The polymer is added tothe fluid either as a solution in a carrier liquid at a pH of about 4.5or as a solid particulate in which the fluid is either modified to a pHof about 4.5 either before, during or after the introduction of thepolymer to it (as further described below) so that the polymer binds allthe negatively charged impurities, such as cells, cell fragments,nucleic acids, viruses, host cell proteins, pyrogens and endotoxins. Thebiomolecule of interest does not interact with the polymer given itspositive net charge due to its basic PI. The pH is then raised to 5-7 ormore if desired and the polymer precipitates out of solution, carryingwith it all the impurities as well as any excess polymer. Theprecipitate can then be easily removed by centrifugation or filtration,resulting in a “purified” biomolecule containing solution.

An example of anionic polyelectrolytes that exhibit this solubilitybehavior is a class of copolymers of acrylic acid and methylmethacrylate or methacrylic acid and methyl methacrylate. These polymersare soluble at a pH greater than about 4-7 and insoluble at a pH lowerthan about 4-7. These polymers can also be used to purify proteins fromcomplex mixtures in a bind and elute mode. For instance, a solution ofthese polymers can be added to a fluid containing a protein of interestin the presence of other impurities wherein the pH of the fluid is at orabove about 4-7. Under these conditions, the negatively charged polymerbinds the positively charged protein of interest (basic PI) while itrepels the negatively charged impurities. The pH of the fluid is thenlowered below about 4-7 to effect precipitation of the polymer-proteincomplex and any excess polymer. The precipitate can then be washed toremove any soluble or loosely bound impurities while the pH is keptbelow about 4-7. The protein can be subsequently eluted from the polymerwith an elution buffer at high salt concentrations and a pH below about4-7 to recover the purified protein.

Examples of a temperature sensitive polymer is agarose, which is oftenused in chromatography, hydroxyalkylcelluloses such ashydroxypropylcellulose; polymers and copolymers containingN-isopropylacrylamide monomer, polyethylene oxide, etc. The temperaturecan then be reduced or raised to cause the polymer to gel and/orprecipitate out of solution.

In some cases, such as with agarose, these polymers are generallyinsoluble at room temperature and are soluble in water or other solventsat temperatures generally between about 80 to 120° C. They can be simplyheated to cause them to dissolve, added to the mixture and then cooledto cause them to precipitate. In other cases, such as with polymers andcopolymers containing N-isopropylacrylamide monomer, the polymer issoluble at a temperature below about 30 to 35° C. and will precipitateout of solution when the temperature is raised above this range.

In the case of agarose the use of gel-inhibiting agents such as varioussalts can depress the solubility temperature to lower temperatures,often to room temperature if desired.

Salts that can be used include lithium chloride and zinc chloride.Bases, such as sodium hydroxide or lithium hydroxide can also be used todepress the gelling temperature or to eliminate it altogether. Althoughthe melting point for agarose is about 92 degrees, the gellingtemperature is about 43 degrees. This gelling temperature can bemanipulated by the modification of the agarose molecule as describedabove or by the addition of the above salts or by a combination thereof.For example, a cationic ligand can be attached to agarose in an amountsuch that the gelling temperature of the modified polymer is about 20°C. degrees with or without the addition of the above salts. The modifiedagarose is added, in solution at a temperature about 25° C. degrees, tothe mixture (also at a temperature of about 25° C. degrees) to bind theconstituents and then the temperature of the mixture is lowered to below20° C. degrees thereby gelling the modified agarose with theconstituents.

With some polymers, such as polyvinylpyridine,polyvinylpyridene-co-styrene and the like, there may be residual monomerleft in the polymer as supplied. It is desirable to remove any freemonomer before using the polymer. One such method is to place thepolymer as purchased in an oven, preferably with an inert or low oxygengas atmosphere such as by purging the oven several times during theprocess with argon or nitrogen, and maintain it at an elevatedtemperature (generally between 100 and 200° C., preferably about 120°C.) and under a vacuum so as to drive off all monomer present (generallyabout 24 hours).

Additionally, with some polymers, such as polyvinylpyridine,polyvinylpyridene-co-sytrene and the like, it is desirable to selecthigher molecular weight polymers (200,000 molecular weight or higher) asthey have been found to more freely precipitate out of solution thanlower molecular weight polymers. This means that one can be sure that noresidual polymer is left in the solution after precipitation.

In some instances, precipitation by itself may be slow or incomplete. Inthose instances, one can repeat the process of changing the stimuliconditions two or more times, add precipitant enhancers such as glassbeads, salts and the like, vary the temperature of the process and thelike to enhance the precipitation.

Typical polymer concentrations in the carrier solvent are between 1-20%by weight depending on the viscosity of the solution. It is preferredthat the concentration be as high as possible to minimize dilution ofthe feedstock. Practically, polymer solutions in the 10-20% arepreferred to achieve a good balance between viscosity and dilution ofthe feedstock. The final concentration of the polymer in the feedstockmay depend on the amount of impurities in the feedstock but it istypically between 0.01% to 2% by weight and more specifically between0.05% and 0.1%.

In some processes one may use two or more polymers either simultaneouslyor sequentially to enhance the impurity removal. For example, one mayuse chitosan as the first polymer and conduct a first purification step.This fluid is separated from the precipitated chitosan/impurities andthen treated with a second polymer such as a polyvinylpyridine tofurther remove impurities.

The recovered biomolecule may then undergo one or more additionalprocessing steps depending on whether it is contained within the liquidof the mixture or is bound to the precipitated polymer.

A method of sequential precipitation may be used to recover thebiomolecule of interest. In such a method, a first precipitation asdescribed above would be used to remove impurities and the precipitatedpolymer/impurities mass would be separated from the target biomoleculecontaining solution. The solution would then be mixed with a stimuliresponsive polymer containing a ligand capable of binding to thebiomolecule of interest at a solution condition at which the polymer issoluble. Following methods described previously, the solution conditionswould be changed so as to precipitate the polymer and bound biomolecule.The polymer/biomolecule would then be separated as previously described,the biomolecule eluted or otherwise separated from the polymer, and therecovered biomolecule further processed as needed.

As the biomolecule of interest is in the liquid, it may, if needed ordesired undergo one or more known process steps including but notlimited to chromatography steps such as ion exchange, hydrophobicinteraction or affinity chromatography, various filtration steps such ashigh performance tangential flow filtration (HPTFF), viralremoval/inactivation steps, final filtration and the like.Alternatively, the biomolecule of interest present in the liquid may beused as is without the need for further purification steps.

The chromatography may be column based using solid bead media ormonoliths or through a membrane absorber or chromatography device. Thestep if desired can be a classic bind/elute or a flow through mode ofchromatography.

Also the biomolecule of interest may undergo further purificationwithout the need for chromatography steps such as through the use ofhigh performance tangential flow filtration using one or more chargedmembranes.

Additionally, in several embodiments, no further purification isrequired. One may if desired add additional steps to ensure that viruseshave been removed or inactivated or to be sure no residual precipitateremains.

A further variation uses an affinity step to bind and then elute thedesired biomolecule. Affinity ligands such as Protein A either on asolid matrix such as a bead or membrane may be used.

In one embodiment of the present invention, the current process simplyreplaces a clarification step and prefilter step in a normal biologicalproduct process train.

In another embodiment, it replaces clarification, prefiltration and atleast one chromatography step by directly purifying the biomolecule ofinterest from the starting materials.

In an additional embodiment, it replaces a cell harvest or biomoleculecollection step by being added directly to the bioreactor or fermentor.This also eliminates the need for clarification, prefiltration andpotentially at least one chromatography step by directly purifying thebiomolecule of interest from the starting materials.

In any of the embodiments of the present invention the protein thusrecovered may be formulated in a pharmaceutically acceptable carrier andis used for various diagnostic, therapeutic or other uses known for suchmolecules.

The mixture that is the starting material of the process will varydepending upon the cell line in which it was grown as well as theconditions under which it is grown and harvested. For example, in mostCHO cell processes the cells express the molecule outside of the cellwall into the media. One tries not to rupture the cells during harvestin order to reduce the amount impurities in the mixture. However, somecells during grow and harvesting may rupture due to shear or otherhandling conditions or die and lyse, spilling their contents into themixture. In bacteria cell systems, the biomolecule is often kept withthe cellular wall or it may actually be part of the cellular wall(Protein A). In these systems the cell walls need to be disrupted orlysed in order to recover the biomolecule of interest.

The target molecule to be purified can be any biomolecule, preferably aprotein, in particular, recombinant protein produced in any host cell,including but not limited to, Chinese hamster ovary (CHO) cells, Per.C6®cell lines available from Crucell of the Netherlands, myeloma cells suchas NSO cells, other animal cells such as mouse cells, insect cells, ormicrobial cells such as E. coli or yeast. Additionally, the mixture maybe a fluid derived from an animal modified to produce a transgenic fluidsuch as milk or blood that contains the biomolecule of interest. Optimaltarget proteins are antibodies, immunoadhesins and other antibody-likemolecules, such as fusion proteins including a C_(H)2/C_(H)3 region. Inparticular, this product and process can be used for purification ofrecombinant humanized monoclonal antibodies such as (RhuMAb) from aconditioned harvested cell culture fluid (HCCF) grown in Chinese hamsterovary (CHO) cells expressing RhuMAb.

Antibodies within the scope of the present invention include, but arenot limited to: anti-HER2 antibodies including Trastuzumab (HERCEPTIN®)(Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992), U.S.Pat. No. 5,725,856); anti-CD20 antibodies such as chimeric anti-CD20“C2B8” as in U.S. Pat. No. 5,736,137 (RITUXAN.®), a chimeric orhumanized variant of the 2H7 antibody as in U.S. Pat. No. 5,721,108, B1,or Tositumomab (BEXXAR.®); anti-IL-8 (St John et al., Chest, 103:932(1993), and International Publication No. WO 95/23865); anti-VEGFantibodies including humanized and/or affinity matured anti-VEGFantibodies such as the humanized anti-VEGF antibody huA4.6.1 AVASTIN®.(Kim et al., Growth Factors, 7:53-64 (1992), International PublicationNo. WO 96/30046, and WO 98/45331, published Oct. 15, 1998); anti-PSCAantibodies (WO01/40309); anti-CD40 antibodies, including S2C6 andhumanized variants thereof (WO00/75348); anti-CD11a (U.S. Pat. No.5,622,700, WO 98/23761, Steppe et al., Transplant Intl. 4:3-7 (1991),and Hourmant et al., Transplantation 58:377-380 (1994)); anti-IgE(Presta et al., J Immunol. 151:2623-2632 (1993), and InternationalPublication No. WO 95/19181); anti-CD18 (U.S. Pat. No. 5,622,700, issuedApr. 22, 1997, or as in WO 97/26912, published Jul. 31, 1997); anti-IgE(including E25, E26 and E27; U.S. Pat. No. 5,714,338, issued Feb. 3,1998 or U.S. Pat. No. 5,091,313, issued Feb. 25, 1992, WO 93/04173published Mar. 4, 1993, or International Application No. PCT/US98/13410filed Jun. 30, 1998, U.S. Pat. No. 5,714,338); anti-Apo-2 receptorantibody (WO 98/51793 published Nov. 19, 1998); anti-TNF-α antibodiesincluding cA2 (REMICADE®), CDP571 and MAK-195 (See, U.S. Pat. No.5,672,347 issued Sep. 30, 1997, Lorenz et al. J. Immunol.156(4):1646-1653 (1996), and Dhainaut et al. Crit. Care Med.23(9):1461-1469 (1995)); anti-Tissue Factor (TF) (European Patent No. 0420 937 B1 granted Nov. 9, 1994); anti-human α₄β₇ integrin (WO 98/06248published Feb. 19, 1998); anti-EGFR (chimerized or humanized 225antibody as in WO 96/40210 published Dec. 19, 1996); anti-CD3 antibodiessuch as OKT3 (U.S. Pat. No. 4,515,893 issued May 7, 1985); anti-CD25 oranti-tac antibodies such as CHI-621 (SIMULECT®) and (ZENAPAX®) (See U.S.Pat. No. 5,693,762 issued Dec. 2, 1997); anti-CD4 antibodies such as thecM-7412 antibody (Choy et al. Arthritis Rheum 39(1):52-56 (1996));anti-CD52 antibodies such as CAMPATH-1H (Riechmann et al. Nature332:323-337 (1988)); anti-Fc receptor antibodies such as the M22antibody directed against FcγRI as in Graziano et al. J. Immunol.155(10):4996-5002 (1995); anti-carcinoembryonic antigen (CEA) antibodiessuch as hMN-14 (Sharkey et al. Cancer Res. 55(23Suppl): 5935s-5945s(1995); antibodies directed against breast epithelial cells includinghuBrE-3, hu-Mc 3 and CRL6 (Ceriani et al. Cancer Res. 55(23):5852s-5856s (1995); and Richman et al. Cancer Res. 55(23 Supp):5916s-5920s (1995)); antibodies that bind to colon carcinoma cells suchas C242 (Litton et al. Eur J. Immunol. 26(1):1-9 (1996)); anti-CD38antibodies, e.g. AT 13/5 (Ellis et al. J Immunol. 155(2):925-937(1995)); anti-CD33 antibodies such as Hu M195 (Jurcic et al. Cancer Res55(23 Suppl):5908s-5910s (1995) and CMA-676 or CDP771; anti-CD22antibodies such as LL2 or LymphoCide (Juweid et al. Cancer Res 55(23Suppl):5899s-5907s (1995)); anti-EpCAM antibodies such as 17-1A(PANOREX®); anti-GpIIb/IIIa antibodies such as abciximab or c7E3 Fab(REOPRO®); anti-RSV antibodies such as MEDI-493 (SYNAGIS®); anti-CMVantibodies such as PROTOVIR®; anti-HIV antibodies such as PRO542;anti-hepatitis antibodies such as the anti-Hep B antibody OSTAVIR®;anti-CA 125 antibody OvaRex; anti-idiotypic GD3 epitope antibody BEC2;anti-αvβ3 antibody VITAXIN®.; anti-human renal cell carcinoma antibodysuch as ch-G250; ING-1; anti-human 17-1A antibody (3622W94); anti-humancolorectal tumor antibody (A33); anti-human melanoma antibody R24directed against GD3 ganglioside; anti-human squamous-cell carcinoma(SF-25); and anti-human leukocyte antigen (HLA) antibodies such as SmartID10 and the anti-HLA DR antibody Oncolym (Lym-1). The preferred targetantigens for the antibody herein are: HER2 receptor, VEGF, IgE, CD20,CD11a, and CD40.

Aside from the antibodies specifically identified above, the skilledpractitioner could generate antibodies directed against an antigen ofinterest, e.g., using the techniques described below.

The antibody herein is directed against an antigen of interest.Preferably, the antigen is a biologically important polypeptide andadministration of the antibody to a mammal suffering from a disease ordisorder can result in a therapeutic benefit in that mammal. However,antibodies directed against non-polypeptide antigens (such astumor-associated glycolipid antigens; see U.S. Pat. No. 5,091,178) arealso contemplated. Where the antigen is a polypeptide, it may be atransmembrane molecule (e.g. receptor) or ligand such as a growthfactor. Exemplary antigens include those proteins described in section(3) below. Exemplary molecular targets for antibodies encompassed by thepresent invention include CD proteins such as CD3, CD4, CD8, CD19, CD20,CD22, CD34, CD40; members of the ErbB receptor family such as the EGFreceptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such asLFA-1, Mac1, p150,95, VLA-4, ICAM-1, VCAM and αv/β3 integrin includingeither α or β subunits thereof (e.g. anti-CD11a, anti-CD18 or anti-CD11bantibodies); growth factors such as VEGF; IgE; blood group antigens;flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; proteinC, or any of the other antigens mentioned herein. Antigens to which theantibodies listed above bind are specifically included within the scopeherein.

Soluble antigens or fragments thereof, optionally conjugated to othermolecules, can be used as immunogens for generating antibodies. Fortransmembrane molecules, such as receptors, fragments of these (e.g. theextracellular domain of a receptor) can be used as the immunogen.Alternatively, cells expressing the transmembrane molecule can be usedas the immunogen. Such cells can be derived from a natural source (e.g.cancer cell lines) or may be cells which have been transformed byrecombinant techniques to express the transmembrane molecule.

Other antigens and forms thereof useful for preparing antibodies will beapparent to those in the art.

Polyclonal antibodies can also be purified in the present invention.Polyclonal antibodies are preferably raised in animals by multiplesubcutaneous (sc) or intraperitoneal (ip) injections of the relevantantigen and an adjuvant. It may be useful to conjugate the antigen to aprotein that is immunogenic in the species to be immunized, e.g.,keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, orsoybean trypsin inhibitor using a bifunctional or derivatizing agent,for example, maleimidobenzoyl sulfosuccinimide ester (conjugationthrough cysteine residues), N-hydroxysuccinimide (through lysineresidues), glutaraldehyde, succinic anhydride, SOCl₂, or R¹N C═NR, whereR and R¹ are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, orderivatives by combining, e.g., 100 μg or 5 μg of the protein orconjugate (for rabbits or mice, respectively) with 3 volumes of Freund'scomplete adjuvant and injecting the solution intradermally at multiplesites. One month later the animals are boosted with ⅕ to 1/10 theoriginal amount of antigen or conjugate in Freund's complete adjuvant bysubcutaneous injection at multiple sites. Seven to 14 days later theanimals are bled and the serum is assayed for antibody titer. Animalsare boosted until the titer plateaus. Preferably, the animal is boostedwith the conjugate of the same antigen, but conjugated to a differentprotein and/or through a different cross-linking reagent. Conjugatesalso can be made in recombinant cell culture as protein fusions. Also,aggregating agents such as alum are suitably used to enhance the immuneresponse.

Monoclonal antibodies are of interest in the present invention and maybe made using the hybridoma method first described by Kohler et al.,Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S.Pat. No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, suchas a hamster or macaque monkey, is immunized as hereinabove described toelicit lymphocytes that produce or are capable of producing antibodiesthat will specifically bind to the protein used for immunization.Alternatively, lymphocytes may be immunized in vitro. Lymphocytes thenare fused with myeloma cells using a suitable fusing agent, such aspolyethylene glycol, to form a hybridoma cell (Goding, MonoclonalAntibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitableculture medium that preferably contains one or more substances thatinhibit the growth or survival of the unfused, parental myeloma cells.For example, if the parental myeloma cells lack the enzyme hypoxanthineguanine phosphoribosyl transferase (HGPRT or HPRT), the culture mediumfor the hybridomas typically will include hypoxanthine, aminopterin, andthymidine (HAT medium), which substances prevent the growth ofHGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stablehigh-level production of antibody by the selected antibody-producingcells, and are sensitive to a medium such as HAT medium. Among these,preferred myeloma cell lines are murine myeloma lines, such as thosederived from MOPC-21 and MPC-11 mouse tumors available from the SalkInstitute Cell Distribution Center, San Diego, Calif. USA, and SP-2 orX63-Ag8-653 cells available from the American Type Culture Collection,Rockville, Md. USA. Human myeloma and mouse-human heteromyeloma celllines also have been described for the production of human monoclonalantibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al.,Monoclonal Antibody Production Techniques and Applications, pp. 51-63(Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed forproduction of monoclonal antibodies directed against the antigen.Preferably, the binding specificity of monoclonal antibodies produced byhybridoma cells is determined by immunoprecipitation or by an in vitrobinding assay, such as radioimmunoassay (RIA) or enzyme-linkedimmunoabsorbent assay (ELISA).

After hybridoma cells are identified that produce antibodies of thedesired specificity, affinity, and/or activity, the clones may besubcloned by limiting dilution procedures and grown by standard methods(Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103(Academic Press, 1986)). Suitable culture media for this purposeinclude, for example, D-MEM or RPMI-1640 medium. In addition, thehybridoma cells may be grown in vivo as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitablyseparated from the culture medium, ascites fluid, or serum byconventional immunoglobulin purification procedures such as, forexample, Pro-Sep® Protein A media available from Millipore Corporationof Billerica, Mass., hydroxyapatite chromatography, gel electrophoresis,dialysis, or affinity chromatography. Preferably the Protein Achromatography procedure described herein is used.

DNA encoding the monoclonal antibodies is readily isolated and sequencedusing conventional procedures (e.g., by using oligonucleotide probesthat are capable of binding specifically to genes encoding the heavy andlight chains of the monoclonal antibodies). The hybridoma cells serve asa preferred source of such DNA. Once isolated, the DNA may be placedinto expression vectors, which are then transfected into host cells suchas E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells,or myeloma cells that do not otherwise produce immunoglobulin protein,to obtain the synthesis of monoclonal antibodies in the recombinant hostcells.

The DNA also may be modified, for example, by substituting the codingsequence for human heavy- and light-chain constant domains in place ofthe homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, etal., Proc. Natl. Acad. Sci. USA, 81:6851 (1984)), or by covalentlyjoining to the immunoglobulin coding sequence all or part of the codingsequence for a non-immunoglobulin polypeptide.

Typically such non-immunoglobulin polypeptides are substituted for theconstant domains of an antibody, or they are substituted for thevariable domains of one antigen-combining site of an antibody to createa chimeric bivalent antibody comprising one antigen-combining sitehaving specificity for an antigen and another antigen-combining sitehaving specificity for a different antigen.

In a further embodiment, monoclonal antibodies can be isolated fromantibody phage libraries generated using the techniques described inMcCafferty et al., Nature, 348:552-554 (1990). Clackson et al., Nature,352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991)describe the isolation of murine and human antibodies, respectively,using phage libraries. Subsequent publications describe the productionof high affinity (nM range) human antibodies by chain shuffling (Markset al., Bio/Technology, 10:779-783 (1992)), as well as combinatorialinfection and in vivo recombination as a strategy for constructing verylarge phage libraries (Waterhouse et al., Nuc. Acids. Res., 21:2265-2266(1993)). Thus, these techniques are viable alternatives to traditionalhybridoma techniques for isolation of monoclonal antibodies.

A humanized antibody has one or more amino acid residues introduced intoit from a source which is non-human. These non-human amino acid residuesare often referred to as “import” residues, which are typically takenfrom an “import” variable domain. Humanization can be essentiallyperformed following the method of Winter and co-workers (Jones et al.,Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327(1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), bysubstituting rodent CDRs or CDR sequences for the correspondingsequences of a human antibody. Accordingly, such “humanized” antibodiesare chimeric antibodies (U.S. Pat. No. 4,816,567) wherein substantiallyless than an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be usedin making the humanized antibodies is very important to reduceantigenicity. According to the so-called “best-fit” method, the sequenceof the variable domain of a rodent antibody is screened against theentire library of known human variable-domain sequences. The humansequence which is closest to that of the rodent is then accepted as thehuman FR for the humanized antibody (Sims et al., J. Immunol., 151:2296(1993)). Another method uses a particular framework derived from theconsensus sequence of all human antibodies of a particular subgroup oflight or heavy chains. The same framework may be used for severaldifferent humanized antibodies (Carter et al., Proc. Natl. Acad. Sci.USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993)).

It is further important that antibodies be humanized with retention ofhigh affinity for the antigen and other favorable biological properties.To achieve this goal, according to a preferred method, humanizedantibodies are prepared by a process of analysis of the parentalsequences and various conceptual humanized products usingthree-dimensional models of the parental and humanized sequences.Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the recipient and import sequences so thatthe desired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.

Alternatively, it is now possible to produce transgenic animals (e.g.,mice) that are capable, upon immunization, of producing a fullrepertoire of human antibodies in the absence of endogenousimmunoglobulin production. For example, it has been described that thehomozygous deletion of the antibody heavy-chain joining region (J_(H))gene in chimeric and germ-line mutant mice results in completeinhibition of endogenous antibody production. Transfer of the humangerm-line immunoglobulin gene array in such germ-line mutant mice willresult in the production of human antibodies upon antigen challenge.See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551(1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann etal., Year in Immuno., 7:33 (1993); and Duchosal et al. Nature 355:258(1992). Human antibodies can also be derived from phage-displaylibraries (Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks etal., J. Mol. Biol., 222:581-597 (1991); Vaughan et al. Nature Biotech14:309 (1996)).

Various techniques have been developed for the production of antibodyfragments. Traditionally, these fragments were derived via proteolyticdigestion of intact antibodies (see, e.g., Morimoto et al., Journal ofBiochemical and Biophysical Methods 24:107-117 (1992) and Brennan etal., Science, 229:81 (1985)). However, these fragments can now beproduced directly by recombinant host cells. For example, the antibodyfragments can be isolated from the antibody phage libraries discussedabove. Alternatively, Fab′-SH fragments can be directly recovered fromE. coli and chemically coupled to form F(ab′)₂ fragments (Carter et al.,Bio/Technology 10:163-167 (1992)). According to another approach,F(ab′)₂ fragments can be isolated directly from recombinant host cellculture. Other techniques for the production of antibody fragments willbe apparent to the skilled practitioner. In other embodiments, theantibody of choice is a single chain Fv fragment (scFv). See WO93/16185.

Multispecific antibodies have binding specificities for at least twodifferent antigens. While such molecules normally will only bind twoantigens (i.e. bispecific antibodies, BsAbs), antibodies with additionalspecificities such as trispecific antibodies are encompassed by thisexpression when used herein.

Methods for making bispecific antibodies are known in the art.Traditional production of full length bispecific antibodies is based onthe coexpression of two immunoglobulin heavy chain-light chain pairs,where the two chains have different specificities (Millstein et al.,Nature, 305:537-539 (1983)). Because of the random assortment ofimmunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of 10 different antibody molecules, of whichonly one has the correct bispecific structure. Purification of thecorrect molecule, which is usually done by affinity chromatographysteps, is rather cumbersome, and the product yields are low. Similarprocedures are disclosed in WO 93/08829, and in Traunecker et al., EMBOJ., 10:3655-3659 (1991).

According to another approach described in WO96/27011, the interfacebetween a pair of antibody molecules can be engineered to maximize thepercentage of heterodimers which are recovered from recombinant cellculture. The preferred interface comprises at least a part of the C_(H)3domain of an antibody constant domain. In this method, one or more smallamino acid side chains from the interface of the first antibody moleculeare replaced with larger side chains (e.g. tyrosine or tryptophan).Compensatory “cavities” of identical or similar size to the large sidechain(s) are created on the interface of the second antibody molecule byreplacing large amino acid side chains with smaller ones (e.g. alanineor threonine). This provides a mechanism for increasing the yield of theheterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or “heteroconjugate”antibodies. For example, one of the antibodies in the heteroconjugatecan be coupled to avidin, the other to biotin. Such antibodies have, forexample, been proposed to target immune system cells to unwanted cells(U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may bemade using any convenient cross-linking methods. Suitable cross-linkingagents are well known in the art, and are disclosed in U.S. Pat. No.4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragmentshave also been described in the literature. For example, bispecificantibodies can be prepared using chemical linkage. Brennan et al.,Science, 229: 81 (1985) describe a procedure wherein intact antibodiesare proteolytically cleaved to generate F(ab′)₂ fragments. Thesefragments are reduced in the presence of the dithiol complexing agentsodium arsenite to stabilize vicinal dithiols and prevent intermoleculardisulfide formation. The Fab′ fragments generated are then converted tothionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives isthen reconverted to the Fab′-thiol by reduction with mercaptoethylamineand is mixed with an equimolar amount of the other Fab'-TNB derivativeto form the bispecific antibody. The bispecific antibodies produced canbe used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab′-SH fragmentsfrom E. coli, which can be chemically coupled to form bispecificantibodies. Shalaby et al., J Exp. Med., 175: 217-225 (1992) describethe production of a fully humanized bispecific antibody F(ab′)₂molecule. Each Fab′ fragment was separately secreted from E. coli andsubjected to directed chemical coupling in vitro to form the bispecificantibody. The bispecific antibody thus formed was able to bind to cellsoverexpressing the ErbB2 receptor and normal human T cells, as well astrigger the lytic activity of human cytotoxic lymphocytes against humanbreast tumor targets.

Various techniques for making and isolating bispecific antibodyfragments directly from recombinant cell culture have also beendescribed. For example, bispecific antibodies have been produced usingleucine zippers. Kostelny et al., J. Immunol., 148(5):1547-1553 (1992).The leucine zipper peptides from the Fos and Jun proteins were linked tothe Fab' portions of two different antibodies by gene fusion. Theantibody homodimers were reduced at the hinge region to form monomersand then re-oxidized to form the antibody heterodimers. This method canalso be utilized for the production of antibody homodimers. The“diabody” technology described by Hollinger et al., Proc. Natl. Acad.Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism formaking bispecific antibody fragments. The fragments comprise aheavy-chain variable domain (V_(H)) connected to a light-chain variabledomain (V_(L)) by a linker which is too short to allow pairing betweenthe two domains on the same chain. Accordingly, the V_(H) and V_(L)domains of one fragment are forced to pair with the complementary V_(L)and V_(H) domains of another fragment, thereby forming twoantigen-binding sites. Another strategy for making bispecific antibodyfragments by the use of single-chain Fv (sFv) dimers has also beenreported. See Gruber et al., J. Immunol., 152:5368 (1994).Alternatively, the antibodies can be “linear antibodies” as described inZapata et al. Protein Eng. 8(10):1057-1062 (1995). Briefly, theseantibodies comprise a pair of tandem Fd segments(V_(H)-C_(H)1-V_(H)-C_(H)1) which form a pair of antigen bindingregions. Linear antibodies can be bispecific or monospecific.

Antibodies with more than two valencies are contemplated. For example,trispecific antibodies can be prepared. Tutt et al. J. Immunol. 147: 60(1991).

The simplest and most straightforward immunoadhesin design combines thebinding domain(s) of the adhesin (e.g. the extracellular domain (ECD) ofa receptor) with the hinge and Fc regions of an immunoglobulin heavychain. Ordinarily, when preparing the immunoadhesins of the presentinvention, nucleic acid encoding the binding domain of the adhesin willbe fused C-terminally to nucleic acid encoding the N-terminus of animmunoglobulin constant domain sequence, however N-terminal fusions arealso possible.

Typically, in such fusions the encoded chimeric polypeptide will retainat least functionally active hinge, C_(H)2 and C_(H)3 domains of theconstant region of an immunoglobulin heavy chain. Fusions are also madeto the C-terminus of the Fc portion of a constant domain, or immediatelyN-terminal to the C_(H)1 of the heavy chain or the corresponding regionof the light chain. The precise site at which the fusion is made is notcritical; particular sites are well known and may be selected in orderto optimize the biological activity, secretion, or bindingcharacteristics of the immunoadhesin.

In a preferred embodiment, the adhesin sequence is fused to theN-terminus of the Fc domain of immunoglobulin G₁ (IgG₁). It is possibleto fuse the entire heavy chain constant region to the adhesin sequence.However, more preferably, a sequence beginning in the hinge region justupstream of the papain cleavage site which defines IgG Fc chemically(i.e. residue 216, taking the first residue of heavy chain constantregion to be 114), or analogous sites of other immunoglobulins is usedin the fusion. In a particularly preferred embodiment, the adhesin aminoacid sequence is fused to (a) the hinge region and C_(H)2 and C_(H)3 or(b) the C_(H)1, hinge, C_(H)2 and C_(H)3 domains, of an IgG heavy chain.

For bispecific immunoadhesins, the immunoadhesins are assembled asmultimers, and particularly as heterodimers or heterotetramers.Generally, these assembled immunoglobulins will have known unitstructures. A basic four chain structural unit is the form in which IgG,IgD, and IgE exist. A four chain unit is repeated in the highermolecular weight immunoglobulins; IgM generally exists as a pentamer offour basic units held together by disulfide bonds. IgA globulin, andoccasionally IgG globulin, may also exist in multimeric form in serum.In the case of multimer, each of the four units may be the same ordifferent.

Various exemplary assembled immunoadhesins within the scope herein areschematically diagrammed below:

(a) AC_(L)-AC_(L);

(b) AC_(H)-(AC_(H), AC_(L)-AC_(H), AC_(L)-V_(H)C_(H), orV_(L)C_(L)-AC_(H));

(c) AC_(L)-AC_(H)-(AC_(L)-AC_(H), AC_(L)-V_(H)C_(H), V_(L)C_(L)-AC_(H),or V_(L)C_(L)-V_(H)C_(H))

(d) AC_(L)-V_(H)C_(H)-(AC_(H), Or AC_(L)-V_(H)C_(H), orV_(L)C_(L)-AC_(H));

(e) V_(L)C_(L)-AC_(H)-(AC_(L)-V_(H)C_(H), or V_(L)C_(L)-AC_(H)); and

(f) (A-Y)_(n)-(V_(L)C_(L)-V_(H)C_(H))₂,

wherein each A represents identical or different adhesin amino acidsequences;

V_(L) is an immunoglobulin light chain variable domain;

V_(H) is an immunoglobulin heavy chain variable domain;

C_(L) is an immunoglobulin light chain constant domain;

C_(H) is an immunoglobulin heavy chain constant domain;

n is an integer greater than 1;

Y designates the residue of a covalent cross-linking agent.

In the interests of brevity, the foregoing structures only show keyfeatures; they do not indicate joining (J) or other domains of theimmunoglobulins, nor are disulfide bonds shown. However, where suchdomains are required for binding activity, they shall be constructed tobe present in the ordinary locations which they occupy in theimmunoglobulin molecules.

Alternatively, the adhesin sequences can be inserted betweenimmunoglobulin heavy chain and light chain sequences, such that animmunoglobulin comprising a chimeric heavy chain is obtained. In thisembodiment, the adhesin sequences are fused to the 3′ end of animmunoglobulin heavy chain in each arm of an immunoglobulin, eitherbetween the hinge and the C_(H)2 domain, or between the C_(H)2 andC_(H)3 domains. Similar constructs have been reported by Hoogenboom, etal., Mol. Immunol. 28:1027-1037 (1991).

Although the presence of an immunoglobulin light chain is not requiredin the immunoadhesins of the present invention, an immunoglobulin lightchain might be present either covalently associated to anadhesin-immunoglobulin heavy chain fusion polypeptide, or directly fusedto the adhesin. In the former case, DNA encoding an immunoglobulin lightchain is typically coexpressed with the DNA encoding theadhesin-immunoglobulin heavy chain fusion protein. Upon secretion, thehybrid heavy chain and the light chain will be covalently associated toprovide an immunoglobulin-like structure comprising two disulfide-linkedimmunoglobulin heavy chain-light chain pairs. Methods suitable for thepreparation of such structures are, for example, disclosed in U.S. Pat.No. 4,816,567, issued 28 Mar. 1989.

Immunoadhesins are most conveniently constructed by fusing the cDNAsequence encoding the adhesin portion in-frame to an immunoglobulin cDNAsequence. However, fusion to genomic immunoglobulin fragments can alsobe used (see, e.g. Aruffo et al., Cell 61:1303-1313 (1990); andStamenkovic et al., Cell 66:1133-1144 (1991)). The latter type of fusionrequires the presence of Ig regulatory sequences for expression. cDNAsencoding IgG heavy-chain constant regions can be isolated based onpublished sequences from cDNA libraries derived from spleen orperipheral blood lymphocytes, by hybridization or by polymerase chainreaction (PCR) techniques. The cDNAs encoding the “adhesin” and theimmunoglobulin parts of the immunoadhesin are inserted in tandem into aplasmid vector that directs efficient expression in the chosen hostcells.

In other embodiments, the protein to be purified is one which is fusedto, or conjugated with, a C_(H)2/C_(H)3 region. Such fusion proteins maybe produced so as to increase the serum half-life of the protein.Examples of biologically important proteins which can be conjugated thisway include renin; a growth hormone, including human growth hormone andbovine growth hormone; growth hormone releasing factor; parathyroidhormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin;insulin A-chain; insulin B-chain; proinsulin; follicle stimulatinghormone; calcitonin; luteinizing hormone; glucagon; clotting factorssuch as factor VIIIC, factor IX, tissue factor, and von Willebrandsfactor; anti-clotting factors such as Protein C; atrial natriureticfactor; lung surfactant; a plasminogen activator, such as urokinase orhuman urine or tissue-type plasminogen activator (t-PA); bombesin;thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and-beta; enkephalinase; RANTES (regulated on activation normally T-cellexpressed and secreted); human macrophage inflammatory protein(MIP-1-alpha); a serum albumin such as human serum albumin;Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain;prorelaxin; mouse gonadotropin-associated peptide; a microbial protein,such as beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associatedantigen (CTLA), such as CTLA-4; inhibin; activin; vascular endothelialgrowth factor (VEGF); receptors for hormones or growth factors; ProteinA or D; rheumatoid factors; a neurotrophic factor such as bone-derivedneurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4,NT-5, or NT-6), or a nerve growth factor such as NGF-β; platelet-derivedgrowth factor (PDGF); fibroblast growth factor such as aFGF and bFGF;epidermal growth factor (EGF); transforming growth factor (TGF) such asTGF-alpha and TGF-beta, including TGF-β1, TGF-β2, TGF-β3, TGF-β4, orTGF-β5; insulin-like growth factor-I and -II (IGF-I and IGF-II);des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor bindingproteins; CD proteins such as CD3, CD4, CD8, CD19, CD20, CD34, and CD40;erythropoietin; osteoinductive factors; immunotoxins; a bonemorphogenetic protein (BMP); an interferon such as interferon-alpha,-beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF,GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxidedismutase; T-cell receptors; surface membrane proteins; decayaccelerating factor; viral antigen such as, for example, a portion ofthe AIDS envelope; transport proteins; homing receptors; addressins;regulatory proteins; integrins such as CD11a, CD11b, CD11c, CD18, anICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 orHER4 receptor; and fragments of any of the above-listed polypeptides.

Examples

The following examples are offered by way of illustration and not by wayof limitation. The disclosures of all citations in the specification areexpressly incorporated herein by reference.

Example 1

This example illustrates the removal of residual 4-vinyl pyridinemonomer from poly(4-vinylpyridine).

Linear poly(4-vinylpyridine), (P4VP) MW 200,000 obtained form ScientificPolymer Products, Inc., was spread evenly on a glass dish and placed ina vacuum oven. The atmosphere inside the oven was purged with argon for5 minutes several times to remove oxygen. The pressure in the oven wasreduced to 0.1 in mercury using a mechanical vacuum pump andsubsequently the temperature was raised to 120° C. The polymer wassubjected to these conditions for a total of 24 hours. During this time,the atmosphere inside the oven was purged with argon for 5 minutesseveral times. At the end of the heating period, the oven temperaturewas lowered to room temperature and the oven was purged with argonseveral times before opening the door. The resulting polymer did nothave a noticeable odor, whereas the untreated polymer has a distinctodor of 4-vinyl pyridine monomer. The amount of residual 4-vinylpyridine monomer present in the treated polymer was not detectable bygel permeation chromatography whereas the untreated polymer had 0.05%(w/w) residual 4-vinyl pyridine monomer

Example 2

This example illustrates the removal of residual 2-vinyl pyridinemonomer from poly(2-vinylpyridine).

Linear poly(2-vinylpyridine), (P2VP) MW 200,000 obtained form ScientificPolymer Products, Inc., was treated exactly according to the process ofexample 1. The resulting polymer did not have a noticeable odor, whereasthe untreated polymer has a distinct odor of 2-vinyl pyridine monomer.

Example 3

This example illustrates the removal of residual 4-vinyl pyridine andstyrene monomers from poly(4-vinylpyridine-co-styrene).

Linear poly(4-vinylpyridine-co-styrene), (P4VP-S), 10% styrene content,obtained form Scientific Polymer Products, Inc., was treated exactlyaccording to the process of example 1. The resulting polymer did nothave a noticeable odor, whereas the untreated polymer has a distinctodor of 4-vinyl pyridine and styrene monomers.

Example 4

This example illustrates the preparation of a poly(4-vinylpyridine)(P4VP) solution.

A 20% (w/w) solution of P4VP was prepared by dissolving 20 g purifiedP4VP, from example 1, in 80 g 1.0 M hydrochloric acid with continuousagitation for 16 hours at room temperature. The resulting viscoussolution was clear and had a slight yellow color.

Example 5

This example illustrates the preparation of a (P2VP) solution.

A 20% (w/w) solution of P2VP was prepared by dissolving 20 g purifiedP2VP, from example 2, in 80 g 1.0 M hydrochloric acid with continuousagitation for 16 hours at room temperature. The resulting viscoussolution was clear and had a slight yellow color.

Example 6

This example illustrates the preparation of a P4VP-S solution.

A 10% (w/w) solution of P4VP-S was prepared by dissolving 10 g purifiedP4VP-S, from example 3, in 90 g 1.0 M hydrochloric acid with continuousagitation for 16 hours at room temperature. The resulting viscoussolution was hazy.

Example 7

This example illustrates the preparation of a chitosan solution.

A 2.5% (w/w) solution of chitosan was prepared by dissolving 2.5 gchitosan, high molecular weight, obtained form Sigma-Aldrich, in 97.5 g0.5 M hydrochloric acid with continuous agitation for 16 hours at roomtemperature.

Example 8

This example illustrates the preparation of a P4VP solution.

A 10% (w/w) solution of P4VP was prepared by dissolving 10 g purifiedP4VP, from example 1, in 90 g 1.0 M hydrochloric acid with continuousagitation for 16 hours at room temperature. The resulting viscoussolution was clear.

Example 9

This example illustrates the response of a “smart” polymer as a resultof a pH stimulus.

About 5 ml of the P4VP solution from example 8 were placed in a testtube, the pH was measured to be below 5. The pH of this solution wasslowly raised to 7 by a dropwise addition of 2N NaOH. The polymerprecipitated out of solution, the color of the precipitate was white andthe decanted liquid was completely clear and colorless suggesting theabsence of any polymer.

Example 10

This example illustrates the removal of a negatively charged dye fromsolution.

About 3 ml of the P4VP solution from example 8 were added to about 5 mlof a solution containing 0.1 ml Ponceau-S (negatively charged dye, redin color) in water. After the addition, the solution was clear and redin color. The pH of the solution was slowly raised to 7 with a few dropsof 2N NaOH, a red precipitate was formed and a clear and colorlessliquid was recovered by decanting. The red precipitate contains all thePonceau S dye that was effectively removed from the liquid phase.

Example 11

This example illustrates the removal of negatively charged impuritiesfrom a cell culture medium containing a monoclonal antibody

The starting feed for the experiment is this example was a raw cellculture medium from a non-expressing line of Chinese Hamster Ovary (CHO)cells incubated in a Wave bioreactor for ten days (sample C), theappearance of this liquid was turbid (due to suspended cell mass) andslightly yellow. Sample C was spiked with a monoclonal antibody (MAb) toa final concentration of about 1 g/L MAb (sample CP), the appearance ofthis liquid did not change following the spike.

The pH of sample C was adjusted to 4.8 with the addition of HCl. To thisliquid, the P4VP solution of example 8 was added in an amount equivalentto about 20% of the starting volume of pH adjusted sample, theappearance of this sample did not change. The pH of the liquid was thenslowly raised to 7 by the dropwise addition of 2N NaOH while mixing. Apale yellow precipitate was formed, which was easily removed bydecanting, the resulting liquid was completely clear and colorless(sample T). This procedure was repeated with sample CP to yield acompletely clear and colorless liquid (sample TP) after the removal ofthe yellow precipitate.

All samples were filtered through 0.2 μm PVDF membranes and analyzed forthe presence of host cell proteins (CHO cell proteins), MAb and DNA.FIGS. 6A and B show SDS-PAGE data for sample C indicates the presence ofa multitude of proteins of varying molecular weights due to CHO cellproteins. Sample CP contains the same population of CHO cell proteins asin sample C as well as the MAb (characteristic molecular weight). Datafor sample T shows no visible bands indicating the absence of proteins.Data for sample TP shows only the characteristic bands for the MAbindicating the presence of pure MAb. Gel electrophoresis data in FIG. 7shows the presence of DNA in samples C and CP while no DNA bands werevisible in samples T and TP indicating the absence of DNA. This exampleshows that this technique is capable of purifying a MAb from a complexmixture of suspended material (cell mass) as well as soluble molecules(host cell proteins and DNA) to result in a pure MAb solution.

SDS-PAGE data as shown in FIGS. 6A and B:

Lanes 3 and 8 are the molecular weight standards. Lane 4 is sample C.Lane 5 is sample CP. Lane 6 is sample T. Lane 7 is sample TP.

Gel electrophoresis data as shown in FIG. 7:

Lane 5 is the molecular weight standards. Lane 6 is sample C. Lane 7 issample CP. Lane 8 is sample T. Lane 9 is sample TP.

Example 12

This example illustrates the use of PVP-S for the removal of cell massfrom a cell culture fluid containing a monoclonal antibody

The starting feed for the experiment is this example was a raw cellculture fluid from an IgG expressing line of Chinese Hamster Ovary (CHO)cells incubated in a Wave bioreactor, the appearance of this liquid wasturbid (due to suspended cell mass) and slightly yellow.

The pH of the starting feed was adjusted to 4.8 with the addition ofHCl. To this fluid, the PVP-S solution of example 6 was added in anamount equivalent to about 0.1% by weight of dry PVP-S relative to thevolume of the starting feed, the appearance of this sample did notchange. The pH of the liquid was then quickly raised to 7 by addition of2N NaOH while mixing vigorously. A pale yellow precipitate was formed,which was easily removed by decanting, the resulting liquid wascompletely clear.

Example 13

This example illustrates the use of chitosan for the removal of cellmass from a cell culture fluid containing a monoclonal antibody

The starting feed for the experiment is this example was a raw cellculture fluid from an IgG expressing line of Chinese Hamster Ovary (CHO)cells incubated in a Wave bioreactor, the appearance of this liquid wasturbid (due to suspended cell mass) and slightly yellow.

The pH of the starting feed was adjusted to 6.5 with the addition ofHCl. To this fluid, the chitosan solution of example 7 was added in anamount equivalent to about 0.06% by weight of dry chitosan relative tothe volume of the starting feed, the appearance of this sample did notchange. The pH of the liquid was then raised to 7.3 by addition of 1NNaOH while mixing. A precipitate was formed, which was easily removed bydecanting, the resulting liquid was completely clear. The turbidity ofthe supernatant was measured to be less than 5 NTU, the turbidity of thestarting feed was in excess of 300 NTU. The removal of DNA by thisprocess was measured to be about 1.5 logs.

Example 14

This example illustrates the use of a mixture of P4VP and chitosan forthe removal of cell mass from a cell culture fluid containing amonoclonal antibody

The starting feed for the experiment is this example was a raw cellculture fluid from an IgG expressing line of Chinese Hamster Ovary (CHO)cells incubated in a Wave bioreactor, the appearance of this liquid wasturbid (due to suspended cell mass) and slightly yellow.

The pH of the starting feed was adjusted to 4 with the addition of HCl.To this fluid, the P4VP solution of example 8 and the chitosan solutionof example 7 were added in amounts equivalent to about 0.1% and 0.06%,respectively, by weight of dry polymer relative to the volume of thestarting feed, the appearance of this sample did not change. The pH ofthe liquid was then raised to 7.3 by addition of 1N NaOH while mixing. Afirst precipitate was formed at pH 5 and a second precipitate wasobserved at pH 7. The solids were then easily removed by decanting, theresulting liquid was completely clear. The turbidity of the supernatantwas measured to be less than 5 NTU.

Example 15

This example illustrates the use of chitosan for the removal of cellmass from a cell culture fluid containing a monoclonal antibody withoutfirst adjusting the pH of the starting feedstock.

The starting feed for the experiment is this example was a raw cellculture fluid from an IgG expressing line of Chinese Hamster Ovary (CHO)cells incubated in a Wave bioreactor, the appearance of this liquid wasturbid (due to suspended cell mass) and slightly yellow. The pH of thefeedstock was about 7.2

Chitosan solution of example 7 was added directly to the startingfeedstock, without adjusting the pH of the feedstock, in an amountequivalent to about 0.06% by weight of dry chitosan relative to thevolume of the starting feed, the appearance of this sample did notchange. The pH of the liquid was then raised to 7.3 by addition of 1NNaOH while mixing. A precipitate was formed, which was easily removed bydecanting, the resulting liquid was completely clear. The turbidity ofthe supernatant was measured to be less than 1 NTU.

Example 16

This example illustrates the synthesis of poly(4-vinyl pyridine-co-vinylpyridinium Sulphopropyl betaine), a water soluble polymer for impurityremoval.

The polymer was synthesized by the direct reaction of poly(4-vinylpyridine), PVP, and 1,3 propane sultone, PS, according to a modifiedliterature technique. The polymer was initially dried in a vacuum ovenat T=100° C. for 48 hr to remove residual monomer. 3 g of PVP weretransferred to the reaction flask and dissolved in 50 ml propylenecarbonate (99%) maintained at T=80° C. under a nitrogen atmosphere. 0.18g of PS was dissolved in 2 ml of propylene carbonate and the solutionwas then added drop wise to the reaction flask. After the completeaddition of the PS solution, the reaction was maintained at 110° C. for12 hr. The mole ratio of the reactants was selected such that theproduct comprises 5 mol % of 4-vinyl pyridinium Sulphopropyl betaine.The resulting reaction mixture was cooled down to room temperature andprecipitated in excess ethylacetate. The precipitate was dried in avacuum oven a T=70° C. for 24 hr.

The polymer was characterized using FTIR which revealed the presence ofthe sulfonate stretches at 1035 cm⁻¹ and 1200 cm⁻¹.

Example 17

This example illustrates the removal of negatively charged impuritiesfrom a cell culture medium containing a monoclonal antibody usingpoly(4-vinyl pyridine-co-vinyl pyridinium sulphopropyl betaine).

0.07 g of the copolymer (10 wt %) from example 16 were mixed with 10 mlfeedstock after adjusting the pH of the latter to 3.5-4.0 using 0.4 g of1M HCl. Following 30 min incubation time, the polymer-cell complexeswere precipitated by increasing the pH gradually to 5.2 using NaOH (1.0M). The precipitate was removed by filtration and the pH of thesupernatant was adjusted to 7.0.

Following this procedure, 85 wt % of IgG was recovered in the clarifiedsupernatant. The quoted numbers are relative to the initial amount ofIgG present in the starting unclarified feedstock.

Example 18

This example illustrates the synthesis of poly(4-vinyl pyridine-co-vinylpyridinium ethylene glycol), a water soluble polymer for impurityremoval.

The polymer was synthesized by the direct reaction of poly(4-vinylpyridine), P4VP, and polyethylene glycol diglycidyl ether (Mn 540 gmol⁻¹). The polymer was initially dried in a vacuum oven at T=100° C.for 48 hr to remove residual monomer. 10 g of P4VP were transferred tothe reaction flask and dissolved in 100 ml methanol, followed by thedrop wise addition of 0.1 g of lithium hydroxide dissolved in 10 mldeionized water. A precipitate was observed upon the addition of thelithium hydroxide solution but re-dissolved within minutes of continuousstirring. After adding 0.15 g of polyethylene glycol diglycidyl ether tothe reaction flask, the mixture was maintained at 80° C. for 24 hrs. Theresulting reaction mixture was then cooled down to room temperature andprecipitated in water. The product was further purified by precipitationfrom an acidic solution by adjusting the solution pH to neutralconditions. The purified polymer was stored in the solution state as 10wt % in 1M HCl.

Example 19

This example illustrates the removal of negatively charged impuritiesfrom a cell culture medium containing a monoclonal antibody usingpoly(4-vinyl pyridine-co-vinyl pyridinium ethylene glycol).

0.04 g of the copolymer (10 wt %) from example 18 were mixed with 8 mlfeedstock after adjusting the pH of the latter to 3.5 using 0.4 g of 1MHCl. Following 10 min incubation time, the polymer-cell complexes wereprecipitated by increasing the pH gradually to 5.2 using NaOH (1M). Theprecipitate was removed by filtration and the pH of the supernatant wasadjusted to 7.0. The turbidity of the supernatant was around 90 NTU,while the turbidity of the starting feedstock was 300 NTU.

1) A method for purifying a biomolecule from a mixture containingimpurities comprising: a. providing the mixture at a set of conditions,b. adding one or more polymers solubilizable in said mixture under theset of conditions, the one or more polymers being capable of binding toone or more of the impurities in the mixture, c. mixing the one or moresolubilized polymers throughout the mixture; d. precipitating the one ormore polymers and one or more bound impurities out of solution bychanging the set of conditions in the mixture; and e. recovering thebiomolecule. 2) The method of claim 1 wherein the one or more polymersare solubilized in carrier liquid before addition to the mixture. 3) Themethod of claim 1 wherein the one or more polymers is caused to besoluble in the aqueous solution due to a pH level and the polymer isprecipitated by a pH change. 4) The method of claim 1 wherein the one ormore polymers is caused to be soluble in the aqueous solution due to apH level below
 7. 5) The method of claim 1 wherein the one or morepolymers is caused to be soluble in the mixture due to a temperature ofthe one or more polymers and the mixture and the one or more polymersprecipitates by a change in the temperature of the one or more polymersand mixture. 6) The method of claim 1 wherein the biomolecule is aprotein. 7) The method of claim 1 wherein the biomolecule is anantibody. 8) The method of claim 1 wherein the biomolecule is arecombinant antibody. 9) The method of claim 1 wherein the biomoleculeis a monoclonal antibody. 10) The method of claim 1 wherein thebiomolecule is a recombinant monoclonal antibody. 11) The method ofclaim 1 wherein the biomolecule is selected from the group consisting ofa polyclonal antibody, a humanized antibody and an antibody fragment.12) The method of claim 1 wherein said biomolecule is an antibodyfragment selected from the group consisting of Fab, Fab^(!), f(ab^(!))₂and Fv fragments, single-chain antibody molecules diabodies, linearantibodies, bispecific antibodies and multispecific antibodies formedfrom antibody fragments. 13) The method of claim 1 wherein saidbiomolecule is an antibody that specifically binds to an antigenselected from the group consisting of CD3, CD4, CD8, CD19, CD20, CD34,CD40, EGF receptor, HER2, HER3, HER4 receptor, LFA-1, Mac1, p150,95,VLA-4, ICAM-1, VCAM, av/b3 integrin, CD11a, CD18, CD11b, VEGF, IgE,flk2/flt3 receptor, obesity (OB) receptor, mpl receptor, CTLA-4 andpolypeptide C. 14) The method of claim 1 wherein said biomolecule is anantibody selected from the group consisting of anti-HER2; anti-CD20;anti-IL-8; anti-VEGF; anti-PSCA; anti-CD11a; anti-IgE; anti-Apo-2receptor; anti-TNF-α, anti-Tissue Factor(TF); anti-CD3; anti-CD25;anti-CD34; anti-CD40; anti-tac; anti-CD4; anti-CD52; anti-Fc receptor;anti-carcinoembryonic antigen (CEA) antibodies; antibodies directedagainst breast epithelial cells; antibodies that bind to colon carcinomacells; anti-CD33; anti-CD22; anti-EpCAM; anti-GpIIb/IIIa; anti-RSV;anti-CMV; anti-HIV; anti-hepatitis; anti-αvβ3; anti-human renal cellcarcinoma; anti-human 17-1A; anti-human colorectal tumor; anti-humanmelanoma; anti-human squamous-cell carcinoma; and anti-human leukocyteantigen (HLA) antibodies. 15) The method of claim 1 wherein saidbiomolecule is an antibody selected from the group consisting ofanti-HER2 receptor, anti-VEGF, anti-IgE, anti-CD20, anti-CD11a, andanti-CD40 antibodies. 16) The method of claim 1 wherein the biomoleculeis an immunoadhesin. 17) The method of claim 1 wherein the biomoleculeis an antibody-like molecule. 18) The method of claim 1 wherein thebiomolecule is an antibody-like molecule and the antibody-like moleculeis a protein fused to, or conjugated with, a C_(H)2/C_(H)3 region. 19)The method of claim 1 wherein the biomolecule is an antibody-likemolecule and the antibody-like molecule is a protein fused to, orconjugated with, a C_(H)2/C_(H)3 region and said protein is selectedfrom the group consisting of rennin; growth hormones; growth hormonereleasing factor; parathyroid hormone; thyroid stimulating hormone;lipoproteins; alpha-l-antitrypsin; insulin A-chain; insulin B-chain;proinsulin; follicle stimulating hormone; calcitonin; luteinizinghormone; glucagons; factor VIIIC; factor IX; tissue factor; vonWillebrands factor; Protein C; atrial natriuretic factor; lungsurfactant; urokinase; human urine and tissue-type plasminogen activator(t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosisfactor-alpha and -beta; enkephalinase; RANTES; human macrophageinflammatory protein (MIP-1alpha); serum albumins; Muellerian-inhibitingsubstance; relaxin A-chain; relaxin B-chain; prorelaxin; mousegonadotropin-associated peptide; beta-lactamase; DNase; IgE, cytotoxicT-lymphocyte associated antigens (CTLAs); inhibin; activin; vascularendothelial growth factor (VEGF); receptors for hormones or growthfactors; Protein A or D; rheumatoid factors; bone-derived neurotrophicfactor (BDNF); neurotrophin-3. -4, -5, and -6 (NT-3, NT-4, NT-5, andNT-6), nerve growth factors; platelet-derived growth factor (PDGF);fibroblast growth factors; epidermal growth factor (EGF); transforminggrowth factors (TGF); insulin like growth factor-I and -II (IGF-I andIGF-II); des(1-3)-IGF-I (brain IGF-I) insulin-like growth factor bindingproteins (IGFBPs); CD proteins; erythropoietin; osteoinductive factors;immunotoxins; bone morphogenetic proteins (BMPs); interferons-alpha,-beta, and -gamma; colony stimulating factors (CSFs); interleukins IL-1to IL-10; superoxide dismutase; T-cell receptors; surface membraneproteins; decay accelerating factor; viral antigens; transport proteins;homing receptors; addressing; regulatory proteins; integrins; tumorassociated antigens; and fragments and thereof. 20) The method of claim1 further comprising the step of incorporating the recovered biomoleculeinto a pharmaceutical formulation. 21) The method of claim 1 wherein theone or more polymers are selected from the group consisting ofpoly(N-isopropylacrylamide), agarose, dextran, polyethylene oxide,cationic polyelectrolytes and anionic polyelectrolytes. 22) The methodof claim 1 wherein the one or more polymers are precipitated by a changein temperature. 23) The method of claim 1 wherein the one or morepolymers are precipitated by a change in temperature and are selectedfrom the group consisting of poly(N-isopropylacrylamide), agaroseHydroxyalkylcellulose and polyethylene oxide. 24) The method of claim 1wherein the one or more polymers are precipitated by a change in pH. 25)The method of claim 1 wherein the one or more polymers are precipitatedby a change in pH and are selected from the group consisting of cationicpolyelectrolytes and anionic polyelectrolytes. 26) The method of claim 1wherein the one or more polymers are precipitated by a change in pH andare cationic polyelectrolytes selected from the group consisting ofchitosan, polyvinylpyridine, copolymers of vinylpyridine, primary aminecontaining polymers, secondary amine containing polymers and tertiaryamine containing polymers. 27) The method of claim 1 wherein the one ormore polymers are precipitated by a change in pH and are anionicpolyelectrolytes selected from the group consisting of copolymers ofacrylic acid and methyl methacrylate and copolymers of methacrylic acidand methyl methacrylate. 28) The method of claim 1 wherein the one ormore polymers are rendered soluble by the condition of temperature andthe mixture is maintained at the desired temperature for period of timeto maintain the one or more polymers in solution and the mixturetemperature is then changed to precipitate out the one or more polymers.29) The method of claim 1 wherein the one or more polymers aresolubilized and precipitated by a change in pH, are cationicpolyelectrolytes selected from the group consisting of chitosan,polyvinylpyridine, copolymers of vinyl pyridine, primary aminecontaining polymers, secondary amine containing polymers and tertiaryamine containing polymers and are soluble at a first pH and areinsoluble at a second pH. 30) The method of claim 1 wherein the one ormore polymers are solubilized and precipitated by a change in pH, arecationic polyelectrolytes selected from the group consisting ofchitosan, polyvinylpyridine, copolymers of vinyl pyridine, primary aminecontaining polymers, secondary amine containing polymers and tertiaryamine containing polymers. 31) The method of claim 1 wherein the one ormore polymers are solubilized and precipitated by a change in pH, areanionic polyelectrolytes selected from the group consisting ofcopolymers of acrylic acid and methyl methacrylate and copolymers ofmethacrylic acid and methyl methacrylate and are soluble at a first pHand are insoluble at a second pH. 32) The method of claim 1 wherein theone or more polymers are added to a carrier liquid under conditions tocause the one or more polymers to go into solution and the carrierliquid containing the one or more polymers in solution is added to themixture through a static mixer. 33) A method for purifying a biomoleculefrom a mixture containing a host cell protein as an impurity comprisingsubjecting said mixture to: a. providing a mixture of a biomolecule anda host cell protein as an impurity, b. conducting a purification step byadding a carrier liquid containing one or more polymers solubilized insaid carrier liquid to the mixture, the polymer being soluble under aset of conditions within the carrier liquid and the mixture and beingcapable of binding to the impurity, c. allowing the one or more polymersto mix with the constituents of the mixture; d. precipitating the one ormore polymers and host cell protein of the mixture out of solution bychanging the set of conditions in the mixture which causes the one ormore polymers to be insoluble; e. filtering the precipitated one or morepolymers from the mixture, and f. recovering the biomolecule at a purityat least 1 LRV better than the initial mixture. 34) The method of claim1 further comprising the recovered biomolecule is formulated in apharmaceutically acceptable carrier. 35) The method of claim 1 furthercomprising the recovered biomolecule is formulated in a pharmaceuticallyacceptable carrier a purpose selected from the group consisting ofresearch, diagnostic and therapeutic purposes. 36) The method of claim 1wherein the one or more polymers are added in excess to the mixture andrecovered as the precipitate. 37) The method of claim 1 furthercomprising subjecting the recovered biomolecule to a second purificationstep in which a stimuli responsive soluble polymer which is capable ofbinding to the biomolecule is added to a mixture containing therecovered biomolecule from the method of claim 1 under conditions tocause the polymer to be in solution, the conditions are changed so as tocause the polymer to precipitate out of solution with the recoveredbiomolecule, recovering the precipitate, eluting the biomolecule fromthe precipitate and recovering the biomolecule. 38) The method of claim1 further comprising subjecting the recovered biomolecule to a secondpurification step in which a stimuli responsive soluble polymer which iscapable of binding to the biomolecule is added to a mixture containingthe recovered biomolecule from the method of claim 1 under conditions tocause the polymer to be in solution, the conditions are changed so as tocause the polymer to precipitate out of solution with the recoveredbiomolecule, recovering the precipitate, washing the precipitate atleast one time, eluting the biomolecule from the precipitate andrecovering the biomolecule. 39) The method of claim 1 wherein theimpurity is selected from the group consisting of DNA, RNA, virus, hostcell proteins, endotoxins, cells, cell fragments and combinationthereof. 40) The method of claim 1 wherein the biomolecule is recoveredby separating the one or more precipitated polymers and one or moreimpurities from the mixture. 41) The method of claim 1 wherein the oneor more polymers are capable of binding with one or more of theimpurities in the solubilized and precipitated state.